Little Caesars Announces Major Change to Menu
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
Little Caesars is doubling down on its reputation as the best value pizza chain by launching a nationwide "More for $9.99 Menu," packed with mix-and-match options to appeal to families, budget-conscious diners, and loyal fans.
The new pricing platform, available exclusively online at participating locations, launched on July 7. It includes options that pair traditional favorites with newer items like the Fantastic Four-N-One Pizza and Crazy Puffs.
The chain says each bundle includes at least two of its most popular menu items, with combinations ranging from two large classic pizzas, to a pretzel crust pizza with Crazy Bread and Crazy Sauce.
Stock image. A Little Caesars restaurant in Los Angeles, California, in 2024.
Stock image. A Little Caesars restaurant in Los Angeles, California, in 2024.)
Why It Matters
This pricing strategy comes amid continued consumer sensitivity to inflation and rising fast food prices. Little Caesars is seeking to differentiate itself in a crowded marketplace where major rivals such as Domino's and Papa John's are also offering a variety of cost-saving deals.
Little Caesars was ranked the fourth best pizza brand by industry magazine PMQ Pizza in its Pizza Power Report 2024, behind Domino's, Pizza Hut and Papa John's.
According to a 2024 report by Datassential, a food and beverage market-research company, Little Caesars was named the most affordable restaurant chain in America. In the survey, 72 percent of diners rated it highly for affordability, outperforming other budget-centric chains like Freshii (65 percent), Papa Murphy's (64 percent), Cici's Pizza (62 percent), and Pollo Tropical (59 percent).
Promotional image of the 'More for $9.99 Menu' deal from Little Caesars.
Promotional image of the 'More for $9.99 Menu' deal from Little Caesars.
Little Caesars
What To Know
Each combo offers at least two products from Little Caesars' lineup, including:
Two large classic cheese or pepperoni pizzas (or one of each)
One classic pepperoni pizza with Crazy Puffs
The new Fantastic Four-N-One Pizza paired with a Crazy Combo (Crazy Bread and Crazy Sauce)
Pretzel Crust Pizza with a Crazy Combo
A party pack of twelve Crazy Puffs, available in cheese, pepperoni, or a mix
There are no minimum purchase requirements and no coupons needed.
What People Are Saying
Greg Hamilton, CMO at Little Caesars, said: "As the value leader in pizza, we don't follow trends — we set them. Our new $9.99 menu is a bold move that provides unbeatable variety and flavor at a price that speaks for itself."
What Happens Next
With the menu only available through early August, it remains unclear whether Little Caesars plans to extend or expand the deal beyond the current promotional window. But its success could influence future strategy.
Until July 31, Newsweek readers can vote for their favorite pizza chain in our Readers' Choice Awards. Winners will be announced on August 7.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Los Angeles Times
5 hours ago
- Los Angeles Times
Raising a family, doing business in California not easy, In-N-Out boss says
There's something about In-N-Out that strikes a fierce if not irrational sense of pride among many Angelenos and Southern Californians. There are several fan clubs and awards, including Yelp's No. 1 Fast Food chain honor earlier this year and Market Force's 2022 'best burger experience.' For some reason, there isn't the same fervor for Southern California's own McDonald's, one of the top 10 brands in the world, or for Santa Barbara's The Habit, which beat In-N-Out in July 2024 for USA Today's best fast food burger accolade. Times readers even lambasted former food columnist Lucas Kwan Peterson when he placed L.A.'s Fatburger atop his fast food burger rankings in 2022. Maybe that's what made the news that Lynsi Snyder, billionaire owner and chief executive of the iconic Baldwin Park brand, was leaving the Golden State last week all the more jarring. Colleague Piper Heath broke down the announcement Monday, while columnist Lorraine Ali opined on what the decision meant. Snyder made an appearance on the podcast 'Relatable' on July 18, hosted by conservative commentator Allie Beth Stuckey. During the interview, Snyder uttered a statement that created shockwaves locally. 'There's a lot of great things about California, but raising a family is not easy here. Doing business is not easy here,' she said as part of her announcement that her business was continuing its eastward expansion. The move to Tennessee represents a seismic shift for the leader of the brand. Currently operating more than 400 locations across eight states — California, Nevada, Arizona, Utah, Oregon, Colorado, Texas and Idaho — In-N-Out has long thrived on being the burger chain you couldn't find everywhere. Snyder's comments set off a disinformation blitz, launching the Double-Double into the middle of a red-state/blue-state culture war where, clearly, nothing is sacred, Ali wrote. Anti-Cali factions incorrectly crowed about yet another business fleeing the West Coast. More proof that Gov. Gavin Newsom's 'failing' state sucks! It appeared that In-N-Out was following Tesla and Charles Schwab, companies that cited regulatory challenges and operational costs among their reasons for relocating. Chevron also fled. Many in SoCal felt abandoned and disrespected. They, after all, propped up the chain for 76 years, only to be told by its owner that the place that made her family's business — their home — is no longer to her liking. On X, Oracle Park Seagull posted ''Not easy for In N Out to do business in California…' Said the person who became a billionaire doing business almost exclusively in California. So much so, it was a point of pride for the chain. Gotcha.' During the podcast, Snyder discussed elements of California policy that make the state hard to operate in, referencing pandemic-era restrictions as particularly challenging. She told Stuckey 'the bulk of our stores are still going to be here in California.' The relocation of both corporate operations and the CEO signals a fundamental change in the company's center of gravity. 'It will be wonderful having an office out there, growing out there, and being able to have the family and other people's families out there,' Snyder said, though she maintains limits on expansion. Newsom even chimed in, starting his X post with, 'For those interested in the facts, rather than fiction, In-N-Out is expanding East — creating a second HQ in Tennessee.' Snyder responded Monday in an Instagram post: 'Where I raise my family has nothing to do with my love and appreciation for our customers in California.' Immigration and ICE raids Trump Administration policy, actions and pushback Crime, courts and policing Health and medicine Get wrapped up in tantalizing stories about dating, relationships and marriage. Have a great weekend, from the Essential California team Jim Rainey, staff writerDiamy Wang, homepage internIzzy Nunes, audience internKevinisha Walker, multiplatform editorAndrew J. Campa, reporterKarim Doumar, head of newsletters How can we make this newsletter more useful? Send comments to essentialcalifornia@ Check our top stories, topics and the latest articles on
New York Times
a day ago
- New York Times
James Leprino, ‘Willy Wonka of Cheese' Who Revolutionized Pizza, Dies at 87
James Leprino, who transformed his family's small Italian grocery store in Denver into a mozzarella empire, producing 85 percent of the cheese for pizzas in the United States as the primary supplier for chains like Domino's, Papa Johns and Pizza Hut, died on June 19. He was 87. Mr. Leprino's death, which has not been widely reported, was announced in a statement from the Leprino Foods Company in Colorado. It did not say where he died or give a cause. Called 'the Willy Wonka of cheese' by Forbes magazine, Mr. Leprino owned a company that industrialized the production and sale of mozzarella, making him a seminal figure in the piping-hot rise of pizza on the American food pyramid, as well as a billionaire twice over. In accelerating the exportation of pizza from neighborhood pizzerias to delivery chains and frozen-food aisles, Mr. Leprino's company had to reinvent the process of making mozzarella. With more than 50 patents for cheese making, Leprino Foods reduced the aging process for mozzarella from 14 days to four hours, created a preservative mist to prevent crumbling and adopted quick-freezing methods that had previously been used for peas. 'The company's production of mozzarella is the envy of the U.S. cheese industry,' The Denver Post Magazine said in 1995. 'The U.S. steel industry found huge productivity gains when it developed technologies to continuously cast long, thin slabs of sheet steel from molten metal. Leprino has perfected the same process with mozzarella.' Want all of The Times? Subscribe.
Business Wire
2 days ago
- Business Wire
ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) Q2 2025 Revenue Growth with Continued Strong Sales Momentum: $26.4 million, up 60% from Q1 2025, with year-to-date sales of ~$43 million. ANKTIVA ® Unit Growth Since J-Code: 246% unit sales volume growth in 1H 2025 compared to 2H 2024. Cash Position: $153.7 million in cash, cash equivalents and marketable securities as of June 30, 2025. NSCLC: Initiated randomized clinical trial (RCT) ResQ201A with N-803 + tislelizumab in 2 nd line lung cancer; US sites initiated, submitted clinical trial applications in EU, UK; Canada and Asia filings planned. Lymphopenia: FDA supportive of new data; reaffirmed RMAT/EAP; collaborative discussion outlining regulatory endpoints, trial design and registrational pathways to full approval for the treatment of lymphopenia with randomized trial design in progress. Full Enrollment Reached in the Randomized NCI Cancer Prevention Clinical Trial Using ANKTIVA + Adenovirus Vaccine in 186 Patients with Lynch Syndrome. United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) marketing authorization application of ANKTIVA approved. Papillary NMIBC: Discussion with FDA regarding filing status of supplemental BLA. ImmunityBio performing ongoing evaluation of next steps to address the Refuse to File decision by the FDA, following June Type A meeting with the Agency. New updated data on Papillary disease provided to the FDA and discussions with Agency to continue. Separately, ImmunityBio has applied to the National Comprehensive Cancer Network (NCCN) to seek expansion of the BCG-unresponsive NMIBC guidelines to include papillary-only disease. Financial Overview In the second quarter of 2025, ImmunityBio reported $26.4 million in revenue, representing a 60% increase from $16.5 million in the first quarter of 2025. This growth reflects continued commercial traction of ANKTIVA + BCG in BCG-unresponsive non-muscle invasive bladder cancer with CIS with or without Papillary tumors. The 1H 2025 sales of $42.9 million represents a 246% increase in unit volume during the first two quarters of 2025 since the J-code approval versus the last two quarters of 2024. The Company ended the quarter with $153.7 million in cash, cash equivalents and marketable securities as of June 30, 2025. Non-Muscle Invasive Bladder Cancer (Papillary NMIBC) ImmunityBio conducted a Type A meeting with the FDA in June to discuss its program targeting papillary-only NMIBC and the Agency's response to the supplemental BLA filing. Contrary to the advice the FDA gave the Company in January 2025 to submit the supplemental BLA, the FDA responded with a Refuse-to-File (RTF) notice in May on the basis of requiring a randomized controlled trial (RCT) against chemotherapy. At the June meeting, ImmunityBio provided new data regarding the updated results since the initial BLA filing of papillary only data as well as real-world data of chemotherapy just published in this indication. In the papillary only NMIBC new data based on 26 of the 100 subjects in Cohort A and 80 subjects in Cohort B (Papillary Alone) of our QUILT-3.032 trial, demonstrated long-term (36-month) progression free survival and bladder sparing with ANKTIVA + BCG. ImmunityBio presented the newly published real-world data which demonstrates that compared to chemotherapy, ANKTIVA + BCG led to improved outcomes of progression free survival and cystectomy avoidance at 36-months. To our knowledge, the results to date of ANKTIVA + BCG represent the longest duration of follow-up with the longest duration of bladder sparing in these subjects. The Company indicated at the meeting that it would seek a new meeting request with this new data and withdraw the prior supplemental BLA filing; however, the Company is re-evaluating this approach in consultation with its regulatory counsel and may seek to amend the initial filing with the new data rather than withdrawing it, with a commitment to initiate a randomized controlled trial of chemotherapy free ANKTIVA + BCG versus chemotherapy in the papillary alone indication. Separately, ImmunityBio has applied to the National Comprehensive Cancer Network (NCCN) to seek expansion of the BCG-unresponsive NMIBC guidelines to include papillary-only disease, in addition to the currently recognized CIS with or without papillary disease. The NCCN is expected to review the submission at its August 2025 meeting. Non-Small Cell Lung Cancer (NSCLC) ImmunityBio has launched ResQ201A, a randomized controlled trial, in the United States, evaluating its IL-15 superagonist N-803 in combination with tislelizumab, a PD-1 checkpoint inhibitor from BeOne Medicines in patients with 2 nd line lung cancer who were progressing on checkpoint inhibitors. The Company has also submitted clinical trial applications for ResQ201A in the European Union and the United Kingdom, with Canada expected to be submitted in early Q3 2025, and with plans underway to submit in Asia. Lymphopenia The Company also met with the Division of Non-Malignant Hematology at the FDA in June to present updated data from its lymphopenia program. The Division was supportive of the findings including the underlying science of stimulating lymphocytes with ANKTIVA and expressed a desire to support an efficient path to approval, noting that additional time will be required to finalize the appropriate development plan. Expanded Access Program (EAP) authorization has been activated for the indication for all solid tumors in patients who have failed first-line treatment on chemotherapy, radiotherapy or immunotherapy and exhibit low Absolute Lymphocyte Counts (ALC < 1,000/μL). Disclaimer Regarding Financial Overview The information and amounts presented above, including under the caption 'Financial Overview,' reflects the Company's preliminary estimates based solely upon information available to it as of the date of this press release, and the amounts reported are not a comprehensive statement of its financial results or position as of June 30, 2025. Any actual amount that the Company reports in its Quarterly Report on Form 10-Q for the period ended June 30, 2025 will be subject to its financial closing procedures and any final adjustments that may be made prior to the time its financial results for the period ended June 30, 2025 are finalized. As a result, these preliminary estimates may differ materially from the actual results that will be reflected in the Company's condensed consolidated financial statements for the quarter when they are completed and publicly disclosed. About ANKTIVA The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved in killing cancer cells. By activating NK cells, ANKTIVA overcomes the tumor escape phase of clones resistant to T cells and restores memory T cell activity with resultant prolonged duration of complete response. ANKTIVA is a first-in-class IL-15 agonist IgG1 fusion complex, consisting of an IL-15 mutant (IL-15N72D) fused with an IL-15 receptor alpha, which binds with high affinity to IL-15 receptors on NK, CD4+, and CD8+ T cells. This fusion complex of ANKTIVA mimics the natural biological properties of the membrane-bound IL-15 receptor alpha, delivering IL-15 by dendritic cells and drives the activation and proliferation of NK cells with the generation of memory killer T cells that have retained immune memory against these tumor clones. The proliferation of the trifecta of these immune killing cells and the activation of trained immune memory results in immunogenic cell death, inducing a state of equilibrium with durable complete responses. ANKTIVA has improved pharmacokinetic properties, longer persistence in lymphoid tissues, and enhanced anti-tumor activity compared to native, non-complexed IL-15 in-vivo. ANKTIVA was approved by the FDA in 2024 and by UK MHRA in 2025 for BCG-unresponsive non-muscle invasive bladder cancer CIS with or without papillary tumors. For more information, visit About ImmunityBio ImmunityBio is a vertically-integrated commercial stage biotechnology company developing next-generation therapies that bolster the natural immune system to defeat cancers and infectious diseases. The Company's range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates natural killer cells, T cells, and memory T cells for a long-duration response. The Company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases. For more information, visit (Founder's Vision) and connect with us on X (Twitter), Facebook, LinkedIn, and Instagram. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding discussions and meetings with the U.S. FDA, including with respect to the previously reported RTF letter received by the Company and potential implications thereof, potential next steps, decisions and timeline related to the Company's regulatory submissions and strategy, financial results anticipated to be reported in future SEC filings, clinical trial data and potential results and implications to be drawn therefrom, the expectation that the EAP described herein will enable patients to have access to ANKTIVA for the indication described, the RMAT designation as previously reported and potential results therefrom and regulatory submissions in connection therewith, the belief that ALC levels and NLR levels obtained from a CBC are predictors of clinical benefit and outcomes relating to overall survival, clinical trial and expanded access program enrollment, timing, data and potential results to be drawn therefrom, anticipated components of ImmunityBio's Cancer BioShield TM platform, anticipated review timeline for the Company's NCCN guidelines submission in NMIBC papillary only and potential implications therefrom, the development of therapeutics for cancer and infectious diseases, potential benefits to patients, potential treatment outcomes for patients, the described mechanism of action and results and contributions therefrom, potential future uses and applications of ANKTIVA alone or in combination with other therapeutic agents for the prevention or reversal of lymphopenia, potential future uses and applications of ANKTIVA alone or in combination with other therapeutic agents across multiple tumor types and indications and for potential applications beyond oncology, potential regulatory pathways and the regulatory review process and timing thereof, the application of the Company's science and platforms to treat cancers or develop cancer vaccines, immunotherapies and cell therapies that have the potential to change the paradigm in cancer care, and ImmunityBio's approved product and investigational agents as compared to existing treatment options, among others. Statements in this press release that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as 'anticipates,' 'believes,' 'continues,' 'goal,' 'could,' 'estimates,' 'scheduled,' 'expects,' 'intends,' 'may,' 'plans,' 'potential,' 'predicts,' 'indicate,' 'projects,' 'is,' 'seeks,' 'should,' 'will,' 'strategy,' and variations of such words or similar expressions. Statements of past performance, efforts, or results of our preclinical and clinical trials, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio's management as well as assumptions made by and information currently available to ImmunityBio. Such information may be limited or incomplete, and ImmunityBio's statements should not be read to indicate that it has conducted a thorough inquiry into, or review of, all potentially available relevant information. Such statements reflect the current views of ImmunityBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) risks and uncertainties regarding the FDA regulatory submission, filing and review process and the timing thereof, (ii) whether the RMAT designation will lead to an accelerated review or approval, of which there can be no assurance, (iii) risks and uncertainties regarding commercial launch execution, success and timing, (iv) risks and uncertainties regarding participation and enrollment and potential results from the expanded access clinical investigation program described herein, (v) whether clinical trials will result in registrational pathways and the risks, (vi) whether clinical trial data will be accepted by regulatory agencies, (vii) the ability of ImmunityBio to continue its planned preclinical and clinical development of its development programs through itself and/or its investigators, and the timing and success of any such continued preclinical and clinical development, patient enrollment and planned regulatory submissions, (viii) potential delays in product availability and regulatory approvals, (ix) ImmunityBio's ability to retain and hire key personnel, (x) ImmunityBio's ability to obtain additional financing to fund its operations and complete the development and commercialization of its various product candidates, (xi) potential product shortages or manufacturing disruptions that may impact the availability and timing of product, (xii) ImmunityBio's ability to successfully commercialize its approved product and product candidates, (xiii) ImmunityBio's ability to scale its manufacturing and commercial supply operations for its approved product and future approved products, (xiv) whether the NCCN will review and/or approve the Company's submission described herein on the anticipated timeline or at all, and (xv) ImmunityBio's ability to obtain, maintain, protect, and enforce patent protection and other proprietary rights for its product candidates and technologies. More details about these and other risks that may impact ImmunityBio's business are described under the heading 'Risk Factors' in the Company's Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 3, 2025, and the Company's Form 10-Q filed with the SEC on May 12, 2025, and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC's website at ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof.
